InSyBio: Strategic-Technological Analysis
17 pages · PDF · 09 November 2025 · Licensed single-user copy, watermarked to the buyer
Tactical Military Medical Tech Artificial Intelligence, Big Data & Analytics
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
InSyBio is a privately held biotechnology startup specializing in AI-driven bioinformatics for biomarker discovery in medicine and nutrition. Founded in 2013 by scientists with European academic backgrounds, it offers an online suite of software tools that integrate multi-omics data to accelerate personalized healthcare research .
Its core capability lies in a patented machine-learning platform that identifies predictive biomarkers (genes, RNAs, proteins) from complex biological datasets, promising higher accuracy with fewer samples .
Key questions this report answers
- What does InSyBio's patented machine-learning platform do to identify predictive biomarkers (genes, RNAs, proteins) from multi-omics data?
- How mature is InSyBio's bioinformatics suite and how does its accuracy-with-fewer-samples claim align with European healthcare and dual-use research needs?
- How does InSyBio's founding by scientists with European academic backgrounds shape its partnerships and market strategy in medicine and nutrition?
- What are InSyBio's capability gaps and dependencies in scaling AI-driven biomarker discovery for personalised healthcare?
Inside this report
- Executive Summary
- Corporate Identity and Legal Structure
- Strategic Business Profile
- Technology Portfolio Mapping
- Technology Readiness Assessment
- European Strategic Program Participation
- Academic and Research Origins
- Dual-Use Applications and European Market Strategy
- Strategic Partnerships and European Industrial Alliances
- European Market Focus and Operational Domains
- Intellectual Property and Innovation Assets
- Leadership and European Technical Expertise
- Capability and Gap Analysis
- Strategic Indicators and European Innovation Metrics
Who it's for
Investors screening InSyBio, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (09 November 2025). You receive a 17-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Military Medical Tech · Artificial Intelligence, Big Data & Analytics · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →